The Covid-19 pandemic brought significant change in areas such as consumer-purchasing preferences, human communication, and workflows.
We focus on identifying long-term beneficiaries in a post-pandemic world.
For example, many businesses that have been resilient and strong during the crisis have become even stronger, taking market share and further cementing their competitive moats.
Danaher develops leading-edge diagnostic tools.
- Diagnostic testing for all types of viruses will become more prevalent as open economies and free movement of people will need to be balanced with safeguards against infectious diseases.
- Several of Danaher's portfolio companies, such as Cepheid, Pall, IDT, and Radiometer, are delivering a significant tailwind to its growth.
- We expect to see a boost in secular demand for Cytiva, Danaher's bioprocessing business, as R&D spend and innovation in the biopharma space should run at structurally elevated levels.
- Combined, we expect normalized mid-to-high single-digit revenue growth for Danaher for several years.